Inhaled corticosteroids (ICSs) are the mainstay of anti-inflammatory treatment in subjects with asthma and COPD. This review evaluates the role of nebulizers as an alternative to inhalers for delivering ICSs in asthma and COPD. I selected 16 randomized, placebo-controlled, blinded, long-term studies, mostly carried out in asthma (n = 14) and COPD. Nebulized budesonide has been demonstrated to be effective and safe in children ages 1–8 years, and, with less evidence, in infants and adults with asthma. Other investigations, with the addition of in vitro and in vivo comparison studies, have shown that nebulized beclomethasone, fluticasone, and flunisolide are effective alternatives to nebulized budesonide in asthma and COPD. Efficient delivery of nebulized ICSs requires that the nebulizer system, the nebulized drug formulation, and the inhaling subject interact properly. The practices of mixing nebulized ICSs with bronchodilators and using nebulized ICSs in acute settings are promising, but require further confirmations, and at present cannot be recommended. I conclude that nebulizers may be considered as an effective alternative to inhalers for delivering ICSs and can be recommended to asthmatic and COPD subjects who are unwilling or unable to use inhalers. Newer formulations could possibly offer a relevant advance for a more efficient nebulization of ICSs.
Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2007. http://www.ginasthma.com. Accessed April 25, 2012.
2.
National Heart, Lung and Blood Institute. Expert panel Report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD: NHLBI; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed April 25, 2012.
3.
BacharierLB, BonerA, CarlsenKH, EigenmannPA, FrischerT, GoetzM, et al. Diagnosis and treatment of asthma in childhood: the PRACTALL consensus report. Allergy, 2008; 63(1):5-34.
4.
McKeanM, DucharmeF. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev, 2000;(2):CD001107.
5.
BisgaardH, HermansenMN, LolandL, HalkjaerLB, BuchvaldF. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med, 2006; 354(19):1998-2005.
6.
BacharierLB, PhillipsBR, ZeigerRS, SzeflerSJ, MartinezFD, LemanskeRFJr, et al; for the Childhood Asthma Research and Education Network of the National Heart, Lung and Blood Institute. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol, 2008; 122(6):1127-1135.
7.
BrandPL, BaraldiE, BisgaardH; on behalf of the ERS Task Force. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence based approach. Eur Respir J, 2008; 32(4):1096-1110.
8.
Castro-RodriguezJA, RodrigoGJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics, 2009; 123(2):e519-e525.
9.
SuissaS, BarnesPJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J, 2009; 34(1):13-16.
10.
PostmaDS, CalverleyP. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J, 2009; 34(1):10-12.
11.
PuhanMA, BachmannLM, KelijnenJ, ter RietG, KesselsAG. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med, 2009; 7:2.
12.
RodrigoGJ. Inhaled corticosteroids as rescue medication in acute severe asthma. Expert Rev Clin Immunol, 2008; 4(6):723-729.
13.
DolovichMB, AhrensRC, HessDR, AndersonP, DhandR, RauJL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest, 2005; 127(1):335-371.
14.
CelliBR, MacNeeW, committee members of ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 2004; 23(6):932-946.
15.
Global Initiative for Chronic Obstructive Lung disease. Global strategy for the diagnosis, management and prevention of COPD. Updated 2006. http://www.goldcopd.com Accessed April 25, 2012.
16.
British Thoracic Society Nebuliser Project Group. Current best practice for nebuliser treatment. Thorax, 1997; 52(Suppl 2):S1-S24.
17.
BoeJ, DennisJH, O'DriscollBR, BauerTT, CaroneM, DautzenbergB, et al. on behalf of a European Respiratory Society Task Force on the use of nebulizers. European Respiratory Society guidelines on the use of nebulizers. Eur Respir J, 2001; 18(2):228-242.
18.
VermeireP. European trends in inhalation therapy. Eur Respir Rev, 1994; 4(18):89-91.
19.
LavoriniF, CorriganCJ, BarnesPJ, DekhuijzenPR, LevyML, PedersenS, et al. on behalf of Aerosol Drug Management Improvement Team. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med, 2011; 105(7):1099-1103.
20.
MelaniAS, PirrelliM, SestiniP, DelDonnoM, BonaviaM, CanessaP, et al; on behalf of the Associazione Italiana Pneumologi Ospedalieri Educational Group. GENebu Project. Equipment and drugs used for home nebulizer therapy in Italy. Monaldi Arch Chest Dis, 2002; 57(5-6):231-236.
21.
ClavennaA, RossiE, BertiA, PedrazziG, DeRosaM, BonatiM; ARNO Working Group. Inappropriate use of antiasthmatic drugs in the Italian paediatric population. Eur J Clin Pharmacol, 2003; 59(7):565-569.
22.
SzeflerSJ. Clinical need for a nebulized corticosteroid. J Allergy Clin Immunol, 1999; 104(Suppl 4):162S-168S.
23.
MarcusP. The role of nebulized inhaled corticosteroid therapy in adult patients with asthma and chronic obstructive pulmonary disease. Adv Ther, 2005; 22(4):407-418.
24.
LefleinJ, BrownE, HillM, KellyHW, LoffertTD, NelsonHS, SzeflerSJ. Delivery of glucocorticoids by jet nebulization: aerosol characteristics and output. J Allergy Clin Immunol, 1995; 95(5 Pt 1):944-949.
KonigP, ShatleyM, LevineC, MawhinneyTP. Clinical observations of nebulized flunisolide in infants and young children with asthma and bronchopulmonary dysplasia. Pediatr Pulmonol, 1992; 13(4):209-214.
27.
AllenED, WhitakerER, RyuG. Six-week trial of nebulized flunisolide nasal spray: efficacy in young children with moderately severe asthma. Pediatr Pulmonol, 1997; 24(6):397-405.
28.
PakesGE, BrogdenRN, HeelRC, SpeightTM, AveryGS. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Drugs, 1980; 19(6):397-441.
29.
JarvisB, FauldsD. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages ≤ 500 μcg/day in adults and adolescents with mild to moderate asthma. Drugs, 1999; 57(5):769-803.
30.
BergerWE. Budesonide inhalation suspension for the treatment of asthma in infants and children. Drugs, 2005; 65(14):1973-1989.
KellerM, JauernigJ, LintzFC, KnochM. Nebulizer nanosuspensions: important device and formulation interactions. Respir Drug Deliver, 2002; 8:197-206.
34.
SchuschnigU, UrbishekM, LuberM, SelzerT, TiffinN, FriedrichI, KellerM. Comparison of delivery efficiency in a nasal cast model of fluticasone propionate suspensions and a novel solution aerosolized via the PARI Vibrent. Respir Drug, 2006; 11:741-743.
35.
KnochM, KellerM. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliver, 2005; 2(2):377-390.
36.
BerlinskiA, WaldrepJC. Effect of aerosol delivery system and formulation on nebulized budesonide output. J Aerosol Med, 1997; 10(1):307-318.
37.
BouwmanAM, HeijstraMP, SchaeferNC, DuivermanEJ, LeSouefPN, DevadesonSG. Improved efficiency of budesonide nebulization using surface-active agents. Drug Deliv, 2006; 13(5):357-363.
38.
AmamiA, ChrystynH, ClarkBJ, AbdelrahimME, YorkP. Evaluation of supercritical fluid engineered budesonide powder for respiratory delivery using nebulisers. J Pharm Pharmacol, 2009; 61(12):1625-1630.
39.
AmamiA, YorkP, ChrystynH, ClarkBJ. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. AAPS Pharm Sci Tech, 2010; 11:1147-1151.
40.
KraftWK, SteigerB, BeussinkD, QuiringJN, FitzgeraldN, GreenbergHE, et al. The parmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol, 2004; 44(1):67-72.
41.
ShrewsburySB, BoscoAP, UsterPS. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharm, 2009; 365(1-2):12-17.
42.
SchueppKG, DevadesonS, RollerC, MinocchieriS, MoellerA, HamacherJ, WildhaberJ. Aerosol delivery of nebulised budesonide in young children with asthma. Respir Med, 2009; 103(11):1738-1745.
43.
BasuK, NairA, WilliamsonPA, MukhopadhyayS, LipworthB. Airway and systemic effects of soluble and suspension formulations of nebulized budesonide in asthmatic children. Ann Allergy Asthma Immunol, 2009; 103(5):436-441.
44.
WilliamsonPA, MenziesD, NairA, TutuncuA, LipworthBJ. A proof-of-concept study to evaluate the anti-inflammatory effects of a novel soluble cyclodextrin formulation of nebulised budesonide in patients with mild to moderate asthma. Ann Allergy Asthma Immunol, 2009; 102(2):161-167.
45.
NikanderK, WunderlichE. Output of budesonide suspension for nebulisation using different Pari jet nebulizer-compressor situations. J Aerosol Med, 1997; 10(1):100S.
46.
BarryPW, O'CallaghanC. Drug output from nebulizers is dependent on the method of measurement. Eur Respir J, 1998; 12(2):463-466.
47.
SmaldoneGC, Cruz-RiveraM, NikanderK. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med, 1998; 11(2):113-125.
48.
BarryPW, O'CallaghanC. An in vitro analysis of the output of budesonide from different nebulizers. J Allergy Clin Immunol, 1999; 104(6):1168-1173.
49.
LuangkhotJ, JauernigJ, BalckeA, LintzFC, Liening-EwertR, StanglR, et al. Characterisation of salbutamol solution compared to budesonide suspensions consisting of submicron and micrometer particles in the PARI LC STAR and a new PARI electronic nebuliser (e-Flow). Drug Deliv Lungs XI, 2000:14-17.
50.
O'CallaghanC, BarryJW, KantarA. Analysis of the output of beclomethasone dipropionate from different nebulisers. Riv Ital Pediatr, 2000; 26:821-824.
51.
FinkJB, UsterP, SimonM. In vitro evaluation of budesonide nebulizing suspension with a novel aerosol generator. J Aerosol Med, 2001; 14:387.
52.
O'CallaghanC, WhiteJ, JacksonJ, BarryPW, KantarA. The output of flunisolide from different nebulisers. J Pharm Pharmacol, 2002; 54(4):565-569.
53.
TservistasM, SommerE, KnochM, HunzikerG. Ultrasonic and perforated-mesh nebulizers: fundamental differences in function and performance. XIV Congress ISAM, BaltimoreJune 2003; P016.
54.
BoscoAP, DolovichMB. Improved aerosolization of suspensions using electronic micropump technology compared to conventional pneumatic nebulization. Chest, 2004; 126(Suppl):816S.
55.
FinkJB, SimmonsR. Nebulization of steroid suspension: an in vitro evaluation of the Aeroneb Go Nebulizer and the Pari LC Plus nebulizers. Chest, 2004; 126(Suppl):816S-817S.
56.
LintzF-C, von OpolskiS, HugM, BucholskiA, KellerM. Development of aqueous solubilized corticoid formulations for nebulization with a vibrating membrane nebulizer. AAPS Annual Meeting, BaltimoreNovember 2004; 1128M.
57.
O'CallaghanC, WhiteJ, JacksonJ, BarryPW, KantarA. Delivery of nebulised budesonide is affected by nebuliser type and breathing pattern. J Pharm Pharmacol, 2005; 57(6):787-790.
58.
SmaldoneGC, BergE, NikanderK. Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med, 2005; 18(3):354-363.
59.
VaghiA, BergE, LiljedahlS, SvenssonJO. In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per aerosol). Pulm Pharmacol Ther, 2005; 18(2):151-153.
60.
ZhouY, AhujaA, IrvinCM, KrackoD, McDonaldJD, ChengYS. Medical nebulizer performance; effects of cascade impactor temperature. Respir Care, 2005; 50(8):1077-1108.
61.
AkapoS, GuptaJ, MartinezE, McCreaC, YeL, RoachM. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. Ann Pharmacother, 2008; 42(10):1416-1424.
62.
BoscoAP, CastilloMC, LuangvalaMM. An in vitro evaluation of the aerosol equivalence of a generic budesonide inhalation suspension: a preliminary critique on equivalence compared to a proprietary budesonide inhalation suspension. Respir Drug Deliver, 2008; 2:619-622.
63.
BoscoAP, CastilloMC, Luangvala. A novel submicron formulation of nebulized budesonide significantly improves the fine particle fraction of drug available for inhalation from various jet nebulizers compared to a marketed budesonide suspension. J Allergy Clin Immunol, 2009; 123(Suppl 1):S594.
64.
HarrisKW, SmaldoneGC. Facial and ocular deposition of nebulized budesonide. Effects of face mask design. Chest, 2008; 133(2):482-488.
65.
LiebermanE, BaiT, HatleyR. Characterization of the performance of a new portable jet nebulizer system for the delivery of budesonide suspension for nebulization. Eur Respir J, 2008; 32:702S.
66.
O'CallaghanC, WhiteJA, JacksonJM, BarryPW, KantarA. Nebulisation of corticosteroids suspensions and solutions with a β2-agonist. J Pharm Pharmacol, 2008; 60(5):601-605.
67.
LuangvalaMM, CastilloMC, BoscoAP. A novel submicron aqueous colloid of budesonide significantly improves the aerodynamic particle sizing distribution of budesonide from various jet nebulizers compared to a marketed suspension (abstract). Am J Respir Crit Care Med, 2009; 179:A2769.
68.
BergE, PicardRJ. In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infants and child breathing patterns. Respir Care, 2009; 54(12):1671-1678.
69.
MelaniAS. Effects on aerosol performances of mixing of either budesonide or beclomethasone dipropionate with albuterol and ipratropium bromide. Respir Care, 2011; 56(3):319-326.
70.
FinlayWH, StapletonKW, ZuberbuhlerP. Predicting regional lung dosages of a nebulized suspension: Pulmicort (budesonide). Particulate Sci Technol, 1997; 15:243-251.
71.
FinlayWH, StapletonKW. Undersizing of droplets from a vented nebulizer caused by aerosol heating during transit through an Andersen impactor. J Aerosol Sci, 1999; 30:105-109.
72.
JauernigJ, SchuschnigU, HugM, KellerM. Validation of a test set-up utilizing the 28.3 L/min Andersen Cascade Impactor (ACI) for the aerodynamic assessment of nebulized aqueous formulations. Respir Drug Delivery, 2002; 8:537-539.
73.
ZhouY, AhujaA, IrvinCM, KrackoD, McDonaldJD, ChengYS. Evaluation of nebulizer performance under various humidity conditions. J Aerosol Med, 2005; 18(3):283-293.
74.
BergE, BockstromK, DahlbackM, NerbrinkO. Output and particle size distribution of Pulmicort suspension generated from MAD2 and Pariboy jet nebulisers. J Aerosol Sci, 1988; 19(7):1093-1096.
75.
DahlbackM. Behavior of nebulizing solutions and suspensions. J Aerosol Med, 1994; 1(7 Suppl):S13-S18.
76.
NikanderK, TurpeinenM, WollmerP. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med, 1999; 12(2):47-53.
77.
NicoliniG, PanzaI. Nebulization of inhaled corticosteroid viscous solutions by ultrasonic nebulizer. Allergy, 2002; 57(Suppl 73):339S.
78.
YoshiyamaY, YazakiT, AraiM, AsaiK, KankeM. The nebulization of budesonide suspensions by a newly designed mesh nebulizer. In: DalbyRN, ByronPR, PeartJ, FarrSF, editors. Respiratory drug delivery, 8th edition. Raleigh: Davis Horvood: 2002; 487-489.
79.
VecellioL. The mesh nebulized: a recent technical innovation for aerosol delivery. Breathe, 2006; 2:253-260.
80.
Lødrup CarlsenKC, NikanderK, CarlsenK-H. How much nebulised budesonide reaches infants and toddlers?. Arch Dis Child, 1992; 67(9):1077-1079.
81.
NikanderK. Drug delivery systems. J Aerosol Med, 1994; 1(7 Suppl):S19-S23.
82.
WennergrenG, NordvallSL, HedlinG, MöllerC, WilleS, Åsbrink-NilssonE. Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Acta Paediatr, 1996; 85(2):183-189.
83.
Vikre-JorgensenJ, AgertoftL, PedersenS. Dose titration of nebulized budesonide in young children. Pediatr Pulmonol, 1997; 23(4):270-277.
84.
AgertoftL, AndersenA, WeibullE, PedersenS. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child, 1999; 80(3):241-247.
85.
NikanderK, BisgaardH. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediatr Pulmonol, 1999; 28(3):187-93.
86.
NikanderK, TurpeinenM, WollmerP. Evaluation of pulsed and breath-synchronized nebulization of budesonide as a means of reducing nebulizer wastage of drug. Pediatr Pulmonol, 2000; 29(2):120-126.
87.
NikanderK, AgertoftL, PedersenS. Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask and mouthpiece) on the inhaled mass of nebulized budesonide. J Asthma, 2000; 37(5):451-459.
88.
GellerDE, KesserKC, JanssensHM, TiddensHA. Delivery of budesonide inhalation suspension (BIS) through an infant upper airway model (abstract). Am J Respir Crit Care Med, 2003; 167:A508.
89.
WestbroekJ, SaarlainenA, LaherM, O'BrienJ, BarnacleH, EfthimiouJ. Oral steroid-sparing effect of two doses of nebulized fluticasone propionate and placebo in patients with severe chronic asthma. Respir Med, 1999; 93(9):689-699.
90.
SmaldoneGC, McKenzieJ, Cruz-RiveraM. Effects of nebulized volume on drug delivery: budesonide inhalation suspension (abstract). Am J Respir Crit Care Med, 2000; 161;(Suppl 3):A36.
91.
MalpassJ, NagelM, DoyleC, AliR, AvvakoumovaV, MitchellY. A breath actuated jet nebulizer has dosimetric capability for a suspension formulation based on differing volume fill of medication as well as run time. Eur Respir J, 2010; 36(Suppl):54.
92.
RosenfeldM, EmersonJ, AstleyS, JoyP, Williams-WarrenJ, StandaertTA, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr, 1998; 132(1):125-131.
93.
PujolMS, MenatC, HenonT, JacquetM, Woronoff LemsiMC. [Prescriptions of aerosol therapy. A survey of practices at the Besançon University Hospital]. Presse Med, 2000; 29:824-828. Article in French.
94.
SallesM, deMonteM, DubusJC, DiotP. [Nebulized corticosteroids and pediatricians: results of the NUAGES survey]. Arch Pediatr, 2008; 15:1520-1524. Article in French.
95.
GronbergS, MagnussonP, BladhN. Chemical compatibility of budesonide inhalation suspension (Pulmicort) with other nebulization products (abstract). Am J Respir Crit Care Med, 2001; 163:A588.
96.
McKenzieJE, Cruz-RiveraM. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother, 2004; 38(6):967-972.
97.
KaminW, SchwabeA, KramerI. Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions. Int J COPD, 2007; 2(4):599-607.
98.
BonasiaPJ, McVicarWK, WilliamsB, OngS. Chemical and physical compatibility of levoalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium. Respir Care, 2008; 53(12):1716-1722.
99.
BonasiaP, CookC, ChengY, OngS. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. Curr Med Res Opin, 2007; 23(10):2477-2483.
100.
BerlinskiA, WaldredJC. Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. J Aerosol Med, 2006; 19(4):484-490.
101.
DiBerardino, ScaglioneF. Mixing albuterol and corticosteroid is not additive. Allergy, 1999; 54(9):1012-1013.
102.
BrattsandR. Development of inhaled steroids: past, present and prospects. Respir Drug Deliver, 2002; 8:1-14.
103.
DerendorfH, NaveR, DrollmannA, CerasoliF, WurstW. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J, 2006; 28(5):1042-50.
104.
WinklerJ, HochhausG, DerenderfH. How the lung handles drugs. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc, 2004; 1:356-363.
105.
GulliverT, MortonR, EidN. Inhaled corticosteroids in children with asthma: pharmacological determinants of safety and efficacy and other clinical considerations. Paediatr Drugs, 2007; 9(3):185-194.
106.
KantarA, MrouehS, FiocchiA. A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. Allergy Asthma Proc, 2007; 28(6):571-587.
107.
DahlstromK, ThorssonL, LarssonP, NikanderK. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Ann Allergy Asthma Immunol, 2003; 90(2):226-232.
108.
SchueppKG, DevadesonS, RollerC, WildhaberJH. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children. Swiss Med Wkly, 2004; 134(13-14):198-200.
109.
BisgaardH, NikanderK, MunchE. Comparative study of budesonide as a nebulized suspension vs pressurized meter-dose inhaler in adult asthmatics. Respir Med, 1998; 92(1):44-49.
110.
MurphyK, NoonanM, SilkoffPE, UryniakT. A 12-week multicenter, randomized, partially blinded, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaler corticosteroids with metered-dose or dry powder inhaler. Clin Ther, 2007; 29(6):1013-1026.
111.
PoliG., AcerbiD. Comparison of the bioavailability and systemic effects of beclomethasone dipropionate suspension for nebulization and beclomethsone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers. Respir Med, 2003; 97(Suppl B):S5-S9.
112.
HaathelaT, JarvinenM, KavaT, KivirantaK, KoskinenS, LehtonenK, et al. Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, Budesonide in newly detected asthma. N Engl J Med, 1991; 325(6):388-392.
113.
BakerJ, MellonM, WaldJ, WelchM, Cruz-RiveraM, Walton-BowenK. A multiple-dosing, placebo-controlled study of budesonide nebulizing suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics, 1999; 103(2):414-421.
114.
JuniperEF, KlinePA, VanzielghemMA, RamsdaleEH, O'ByrnePM, HargreaveFE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis, 1990; 142(4):832-836.
115.
WaalkensHJ, van Essen-ZandvlietEE, HughesMD, GerritsenJ, DuivermanEJ, KnolK, et al. Cessation of long-term treatment with inhaled corticosteroid (budesonde) in children with asthma results in deterioration. Am Rev Respir Dis, 1993; 148(5):1252-1257.
116.
HaathelaT, JarvinenM, KavaT, KivirantaK, KoskinenS, LehtonenK, et al. Effects of reducing or discontinuiing inhaled budesonide in patients with mild asthma. N Engl J Med, 1994; 331(10):700-705.
117.
GrimfeldA, LesbrosD, OstinelliJ, CaswellC. Long term study of nebulized budesonide in young children with moderate to severe asthma. Eur Respir J, 1994; 7(Suppl 18):27S.
118.
PauwelsRA, LofdahlC-G, PostmaDS, Tattersfield, O'ByrneP, BarnesP, UllmanA, for the Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. N Engl J Med, 1997; 337(20):1405-1411.
119.
SzeflerSJ, MartinRJ, KingTS, BousheyHA, CherniackRM, ChinchilliVM, et al. Significant variability in response to inhaled corticosteroid for persistent asthma. J Allergy Clin Immunol, 2002; 109(3):410-418.
120.
BatemanED, BousheyHA, BousquetJ, BusseWW, ClarkTJH, PauwelsRA, PedersenSE, for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med, 2004; 170(8):836-844.
121.
MasoliM, HoltS, WeatherallM, BeasleyR. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J, 2004; 23(4):552-558.
122.
MasoliM, WeatherallM, HoltS, BeasleyR. Systematic review of the dose–response relation of inhaled fluticasone propionate. Arch Dis Child, 2004; 89(10):902-907.
123.
O'ByrnePM, BisgaardH, GodardPP, PistolesiM, PalmqvistM, ZhuY, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med, 2005; 171(2):129-136.
124.
BeasleyR, SterkPJ, KerstjensHA, DecramerM. Comparative studies of inhaled corticosteroids in asthma. Eur Respir J, 2001; 17(4):579-580.
125.
PiacentiniGL, SetteL, PeroniDG, BonizzatoC, BonettiS, BonerAL. Double-blind evaluation of effectiveness and safety of flunisolide aerosol for treatment of bronchial asthma in children. Allergy, 1990; 45(8):612-616.
126.
van BeverHP, SchuddinckL, WojciechowskiM, StevensJW. Aerosolised budesonide in asthmatic infants: a double blind study. Pediatr Pulmonol, 1990; 9(3):177-180.
127.
IlangovanP, PedersenP, GodfreyS, NikanderK, NoviskiN, WarnerJO. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child, 1993(3):68:356-359.
128.
DeBenedictisFM, MartinatiLC, SolinasLF, TuteriG, BonerAL. Nebulized flunisolide in infants and young children with asthma: a pilot study. Pediatr Pulmonol, 1996; 21(5):310-315.
129.
DeBlicJ, DelacourtC, LeBourgeoisM, MahutB, OstinelliJ, CaswellC, ScheinmannP. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol, 1996; 98(1):14-20.
130.
ShapiroG, BronskyEA, LaForceCF, MendelsonL, PearlmanD, SchwartzRH, SzeflerSJ. Dose-related efficacy of budesonide administered via dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr, 1998; 132(6):976-982.
131.
KempJP, SkonerDP, SzeflerSJ, Walton-BowenK, Cruz-RiveraM, SmithJA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol, 1999; 83(3):231-239.
132.
MelaniAS, DiGregorioA. Four-week nebulized beclomethasone dipropionate in stable COPD patients with exertional dyspnoea. Monaldi Arch Chest Dis, 1999; 54(3):224-227.
133.
PiacentiniGL, BodiniA, CostellaS, VicentiniL, MazziP, SuzukiY, et al. Exhaled nitric oxide in asthmatic children exposed to relevant allergens: effect of flunisolide. Eur Respir J, 2000; 15(4):730-734.
134.
BergerWE, QaqundahPY, BlakeK, Rodriguez-SantanaJ, IraniAM, XuJ, GoldmanM. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr, 2005; 146(1):91-95.
PaggiaroPL, VagagginiB, DiFrancoA, ZingoniM, FanoM, BiraghiM, on behalf of the COGNE Study group. Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease. Respiration, 2006; 73(5):603-606.
137.
PapiA, NicoliniG, BaraldiE, BonerAL, CutreraR, RossiGA, FabbriLM, on behalf of the Beclomethasone and Salbutamol Treatment (BEST) for Children Study group. Regular vs prn nebulized treatment in wheeze preschool children. Allergy, 2009; 64(10):1463-1471.
138.
ScottMB, SkonerDP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol, 1999; 104(4 Pt 2):200S-209S.
139.
CetinkayaF, KayiranP, MemiogluN, TarimOF, ErenN, ErdemE. Effects of nebulized corticosteroids on hypothalamic-pituitary-adrenal axis in young children with recurrent or persistent wheeze. Pediatr Allergy Immunol, 2008; 19:773-776.
140.
SkonerDP, SzeflerSJ, WelchM, Walten-BowenK, Cruz-RiveraM, SmithJA. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol, 2000; 105(2):259-268.
141.
AgertoftL, PedersenS. Effect of long term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med, 2000; 343(15):1064-1069.
142.
Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med, 2000; 343(15):1054-1063.
143.
GuilbertTW, MorganWJ, ZeigerRS, MaugerDT, BoehmerSJ, SzeflerSJ, et al, Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med, 2006; 354(19):1985-1997.
144.
MurrayCS, WoodcockA., LangleySJ, MorrisJ, CustovicA. Secondary prevention of asthma by the use of inhaled fluticasone proprionate in wheezy infants: double-blind randomized, controlled study. Lancet, 2006; 368(9537):754-762.
145.
Cruz-RiveraM, LyzellE, FitzpatrickS. Low frequency of adverse events reported through postmarketing surveillance for Pulmicort Respules (budesonide inhalation suspension) in the US adult population. J All Clin Immunol, 2002; 109(Suppl 292):abstract 895.
146.
LyzellE, Cruz-RiveraM, FitzpatrickS. Safety of Pulmicort Respules (budesonide inhalation suspension) in geriatric patients: postmarketing surveillance and clinical study data. J All Clin Immunol, 2002; 109(Suppl 292):abstract 894.
147.
GreenbergerPA, PattersonR. Beclomethasone dipropionate for severe asthma during pregnancy. Ann Intern Med, 1983; 98(4):478-480.
148.
EricsonA, KallenB. Use of drugs during pregnancy-unique Swedish registration method that can be improved. Information from the Swedish Medical Products Agency, 1999; 1:8-11.
149.
KallenB, RydhstroemH, AbergA. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol, 1999; 93:392-395.
150.
NorjavaaraE, Gerhardsson de VerdierM. Normal pregnancy outcomes in a population based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol, 2003; 111(1):736-742.
151.
SangwanS, GursesBK, SmaldoneGC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol, 2004; 37(5):447-452.
152.
SzeflerSJ, FitzpatrickS, Cruz-RiveraM, LyzellE. Lack of cataracts and other localized adverse events in children treated with nebulized Pulmicort Respules [Budesonide inhalation suspension] (abstract). Am J Respir Crit Care Med, 2001; 163:A589.
153.
PetersSP. Safety of inhaled corticosteroids in the treatment of persistent asthma. J Nat Med Assoc, 2006; 98(6):851-861.
154.
PedersenS, HansenOR. Dose-response relationships to nebulized budesonide in children with asthma (abstract). Am J Respir Crit Care Med, 1997; 155(2 part 2):A268.
155.
VolovitzB, SofermanR, BlauH, NussinovitchM, VarsanoI. Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes. J Allergy Clin Immunol, 1998; 101(4):464-469.
156.
Lødrup CarlsenKC, CarlsenK-H, NikanderK, LeegaardJ, HavnenJ, Steen-JohnsenJ, WinsnessA. Nebulized budesonide after hospitalization for recurrent bronchial obstruction in children younger than 18 months. Pediatr Allergy Immunol, 2001; 12(3):159-165.
157.
PriceJ, LenneyW, DuncanC, GreenL, FloodY, Daley-YatesP, et al. HPA-axis effects of nebulised fluticasone propionate compared with oral prednisolone in childhood asthma. Respir Med, 2002; 96(8):625-631.
158.
BiscaN, CernatescuI, DragomirD, IacomiA, MirceauM, OrascanuD. Comparison of the efficacy and safety of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in paediatric patients with moderate to severe exacerbation of asthma. Respir Med, 2003; 97(Suppl. B):S15-S20.
159.
BousquetJ, MezianeH, ChanezP, MueserM, UmileA. The response of two different dosages of beclometasone dipropionate suspension for nebulization versus a standard dose of beclometasone dipropionate via a metered-dose inhaler on bronchoprovocation testing in adults with asthma. Respir Med, 2003; 97(Suppl B):S11-S14.
160.
Grzelewska-RzymowskaI, Kroczynska-BednarekJ, ZarkovicJ. Comparison of the efficacy and safety of high doses of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in steroid-dependent adults with moderate to severe asthma. Respir Med, 2003; 97(Suppl B):S21-S26.
161.
VolovitzB, NussinovitchM. Effect of high starting dose of budesonide inhalation suspension on serum cortisol concentration in young children with recurrent wheezing episodes. J Asthma, 2003; 40(6):625-629.
162.
DeBenedictisFM, Del GiudiceMM, VetrellaM, TressantiF, TronciA, TestiR, DasicG, FLIC12 Study Group. Nebulized fluticasone proprionate vs budesonide as adjunctive treatment in children with asthma exacerbation. J Asthma, 2005; 42(5):331-336.
163.
ZielenS, RoseMA, BezC, JarischA, ReichenbachJ, HofmannD. Effectiveness of budesonide nebulising suspension compared to disodium cromoglycate in early childhood asthma. Curr Med Res Opin, 2006; 22(2):367-373.
164.
La GruttaS, NicoliniG, CapristoC, BellodiSC, RossiGA. Once daily nebulized beclomethasone is effective in maintaining pulmonary function and improving symptoms in asthmatic children. Monaldi Arch Chest Dis, 2007; 67(1):30-38.
165.
DecimoF, MaielloN, Miraglia Del GiudiceM, AmelioR, CapristoC, CapristoAF. High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. Int J Immunopathol Pharmacol, 2009; 22(2):363-370.
PedersenW, PrahlP. Jet-nebulized beclomethasone dipropionate in the management of bronchial asthma. Topical steroids for asthmatic children younger than 4 years. Allergy, 1987; 42(2):272-275.
169.
O'CallaghanC. Particle size of beclomethasone dipropionate produced by two nebulisers and two spacing devices. Thorax, 1990; 45(2):109-111.
170.
WalesD, MakkerH, KaneJ, McDowellP, O'DriscollBR. Systemic bioavailability and potency of high-dose inhaled corticosteroids. A comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest, 1999; 115(5):1278-1284.
171.
DempseyOJ, HumphreysM, CoutieWJ, LipworthBJ. Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers. Eur J Clin Pharmacol, 2001; 57(9):637-641.
172.
MendelsonL, CookD, Cruz-RiveraM, FitzpatrickS, SmithJA. Twice-daily budesonide inhalation suspension in infants and children <4 and > or = 4 years of age with persistent asthma. J Asthma, 2002; 39(3):227-237.
173.
DaugbjergP, BrenoeE, ForchhammerH, FrederiksenB, GlazowskiMJ, Ibsen KaasK, et al. A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age. Acta Paediatr, 1993; 82(6-7):547-551.
174.
BautistaMS, BalderasJ. The efficacy of combined inhaled steroids and β2 agonist in the treatment of acute asthma in children 6-18 years of age versus inhaled β2 agonist alone. Eur Respir J, 1994; 7(Suppl 18):93S.
175.
SungL, OsmondMH, KlassenTP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med, 1998; 5(3):209-213.
176.
TsaiYG, LeeMY, YangKD, ChuDM, YuhYS, HungCH. A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma. J Pediatr, 2001; 139(3):433-437.
177.
MaltaisF, OstinelliJ, BourbeauJ, TonnelAB, JacquemetN, HaddonJ, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med, 2002; 165(5):698-703.
178.
MilaniGKM, Rosario FilhoNA, RiediCA, FigueiredoBC. Nebulized budesonide to treat acute asthma in children. Jornal de Pediatria, 2004; 80(2):106-112.
179.
Estrada-ReyesE, Del Rio NavarroBE, Rosas-VargasMA, Nava-OcampoAA. Co-administration of salbutamol and fluticasone for emergency treatment of children with moderate acute asthma. Paediatr Allergy Immunol, 2005; 16(7):609-614.
180.
NuhogluY, AtasE, NuhogluC, IscanM, OzcayS. Acute effect of nebulized budesonide in asthmatic children. J Invest Allerg Clin Immunol, 2005; 15(3):197-200.
181.
SekerelBE, SackesenC, TuncerA, AdaliogluG. The effect of nebulized budesonide treatment in children with mild to moderate exacerbations of asthma. Acta Paediatr, 2005; 94(10):1372-1377.
182.
GunenH, HacievliyagilSS, YetkinO, GolbasG, CemL, InE. The role of nebulized budesonide in the treatment of exacerbations of COPD. Eur Respir J, 2007; 29(4):660-667.
183.
CamargoCAJr., RachelefskyG, SchatzM. Managing asthma exacerbations in the emergency department: Summary of the National Asthma Education and Prevention Program Export Panel Report 3 guidelines for the management of asthma exacerbations. J Allergy Clin Immunol, 2009; 124(Suppl 2):S5-S14.
184.
HenzenC, SuterA, LerchE, UrbinelliR, SchornoXH, BrinerVA. Suppression and recovery of adrenal response after short-term high-dose glucocrticoid treatment. Lancet, 2000; 355(9203):542-545.
185.
DucharmeFM, OchsHD, ResendesS, ZhangX, MazerDB. A short burst of oral corticosteroid for children with acute asthma: is there an impact on immunity?. Pediatric Allergy Immunology Pulmonogy, 2010; 23(4):243-252.
186.
MitchellCA, AlpersJH, MortonSM, BaggoleyCJ, CrokerWD, WalshAJ, et al. Comparison of nebulized budesonide with oral prednisolone in the treatment of severe acute asthma. Eur Respir J, 1995; 8(Suppl):490S.
187.
FrancisP, GeelhoedG, HarrisMA, MortonJ, EfthimiouJ, BarnacleH. Effect of nebulised fluticasone propionate 1 mg twice daily compared with oral prednisolone in pre-school chidren aged 48 months or less with an acute exacerbation of asthma. Eur Respir J, 1997; 10(Suppl 25):275S.
188.
WinterJH, DhillonDP, WinterJE, FeeneyY, AllenD, MaslenT. Effect of the early substitution of nebulised fluticasone propionate 2 mg bd for oral prednisolone 50 mg od in adults during the early recovery period of an acute exacerbation of asthma. Eur Respir J, 1997; 10:174S.
189.
Devidayal, SinghiS, KumarL, JayshreeM. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr, 1999; 88(8):835-840.
190.
MatthewsEE, CurtisPD, McLainBI, MorrisLS, TurbittML. Nebulized budesonide verus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr, 1999; 88(8):841-843.
191.
ManjraAI, PriceJ, LenneyW, HughesS, BarnacleH. Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respir Med, 2000; 94(12):1206-1214.
192.
SanoF, CortezGK, SoleD, NaspitzCK. Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone. J Allergy Clin Immunol, 2000; 105(4):699-703.
193.
RaziCH, TurktasI, BakirtasA. Comparison of single 2000-μg dose treatment vs sequential repeated-dose 500-μg treatments with nebulized budesonide in acute asthma exacerbations. Ann Allergy Asthma Immunol, 2008; 100(4):370-376.
194.
WilsonAM, McFarlaneLC, LipworthBJ. Systemic bioactivity profiles of oral prednisolone and nebulized budesonide in adult asthmatics. Chest, 1998; 114(4):1022-1027.
195.
RhenT, CidlowskiJA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med, 2005; 353(16):1711-1723.
196.
HorvathG, WannerA. Inhaled corticosteroids: effects of the airways vasculature in bronchial asthma. Eur Respir J, 2006; 27(1):182-187.
197.
BeldaJ, MargaritG, MartinezC, Bellido-CasadoJ, CasanP, TorrejónM, et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisolone in asthma exacerbations. Eur Respir J, 2007; 30(6):1143-1149.
198.
RodrigoGJ. Rapid effects of inhaled corticosteroids in acute asthma. An evidence-based evaluation. Chest, 2006; 130(5):1301-1311.
199.
EdmondsML, CamargoCAJr, BrennerB, RoweBH. Inhaled steroids in acute asthma following emergency department discharge. Cochrane Database Syst Rev, 2000; 3:CD002316.
200.
EdmondsML, CamargoCAJr, PollackCVJr, RoweBH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev, 2003;(3):CD002308.
201.
VolovitzB. Inhaled budesonide in the management of acute worsenings and exacerbations of asthma: a review of the evidence. Respir Med, 2007; 101(4):685-695.
202.
ParkinPC, SaundersNR, DiamondSA, WindersPM, MacarthurC. Randomised trial spacer v. nebuliser for acute asthma. Arch Dis Child, 1995; 72(3):239-240.
203.
MasonN, RobertsN, YardN, PartridgeMR. Nebulisers or spacers for the administration of bronchodilators to those with asthma attending emergency departments?. Respir Med, 2008; 102(7):993-998.
204.
MelaniAS, SestiniP, AiolfiS, BarbatoN, CanessaP, DeAngelisG, et al; on behalf of the Associazione Italiana Pneumologi Ospedalieri (AIPO) Educational Group. GENebu Project: home nebulizer use and maintenance in Italy. Eur Respir J, 2001; 18(4):758-763.
205.
RachelefskyG. Inhaled corticosteroids and asthma control in children: assessing impairment and risk. Pediatrics, 2009; 123:353-366.
MelaniAS, BonaviaM, CilentiV, CintiC, LodiM, MartucciP, et al; on behalf of the Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri (AIPO). Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med, 2011; 105(6):930-938.
208.
RobertsCM, LoweD, BucknallCE, RylandI, KellyY, PearsonMG; on behalf of the British Thoracic Society Audit Subcommittee of the Standards of Care Committee and the Royal College of Physicians of London. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax, 2002; 57(2):137-141.
209.
KrishnanJA, DemottM, McCoyJV, ChanmugamA, RandCS. Nebulized beta2-agonist use in high-risk inner-city adults with asthma. J Asthma, 2003; 40(4):367-373.
210.
MarcusP, OppenheimerEA, PatelPA, KatzLM, DoyleJJ. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcome. Ann Allergy Asthma Immunol, 2006; 96(5):736-743.
211.
CamargoCAJr, RamachandranS, RyskinaKL, LewisBE., LegorretaAP. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm, 2007; 64(10):1054-1061.
212.
McLaughlinT, LeibmanC, PatelP, CamargoCAJr. Risk of recurrent emergency department visits or hospitalizations in children with asthma receiving nebulized budesonide inhalation suspension compared with other asthma medications. Curr Med Res Opin, 2007; 23(6):1319-1328.
213.
SchueppKG, JauernigJ, JanssensHM, TiddensHA, StraubDA, StanglR, et al. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med, 2005; 18(2):225-235.
214.
AmiravI, NewhouseMT, MinocchieriS, Castro-RodriguezJA, SchueppKG. Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol, 2010; 125(6):1206-1211.
